Scheduling Conferences in Tylenol Litigation Set Through Year’s End

The U.S. District Judge presiding over all Tylenol liver failure lawsuits filed in the federal court system has established a schedule for status conferences that will be held through the end of the year, with the parties and the Court meeting on a monthly basis as pretrial proceedings in the litigation get underway.

In April, the U.S. Judicial Panel on Multidistrict Litigation consolidated all product liability lawsuits involving allegations that Johnson & Johnson failed to adequately warn about the risk of liver problems from Tylenol, centralizing cases brought nationwide before U.S. District Judge Lawrence F. Stengel in the Eastern District of Pennsylvania.

According to a case management order (PDF) issued July 11, status conferences will be held before Judge Stengel on August 22, September 24, October 22, November 19 and December 17. Lawyers appointed to leadership roles in the Tylenol litigation have been directed to submit joint written statements in advance of each conference, providing a status report and proposed agenda for each meeting.

Tylenol Autism Lawsuit

Does your child have Austism from Tylenol Exposure?

Side effects of Tylenol may cause autism and ADHD among children exposed during pregnancy. Find out if your family may be eligible for a Tylenol autism or ADHD settlement.

Learn More See If You Qualify For Compensation

Tylenol is a popular painkiller that has been widely used by millions of Americans, containing acetaminophen as the active pharmceutical ingredient. Side effects of acetaminophen have been linked to a risk of liver injury for decades, and the lawsuits allege that Johnson & Johnson and McNeil have withheld information from consumers about the risks associated with taking too much of the widely used pain killer.

While there are currently only a few dozen Tylenol cases pending before Judge Stengel, the number of lawsuits is expected to continue to grow as lawyers review and file additional cases for individuals who developed liver failure following an overdose of Tylenol.

All of the complaints involve similar claims that Johnson & Johnson built an image for their blockbuster medication as safe and effective by withholding important information about the link between Tylenol and liver problems.

The FDA has previously identified acetaminophen as the leading cause of liver injury in the United States. It has been suggested that more than 50,000 emergency room visits each year are caused by acetaminophen, including 25,000 hospitalizations and 450 deaths.

In recent years, there has been an increased effort to bring information about the risk of overdosing on acetaminophen to the public’s attention and to reduce the number of liver failure cases linked to the popular analgesic, which is also found in other pain killers and a number of cold medications. Earlier this month, yet another reminder was issued by the FDA about the potential liver risks with Tylenol and other acetaminophen products, indicating that consumers should be careful about taking too much acetaminophen or combining multiple products that contain the same active pharmaceutical ingredient.

Johnson & Johnson lowered the maximum recommended dosage on Tylenol and other acetaminophen-based products from 4,000 mg per day to 3,000 mg per day in 2011, after the FDA announced new limits on acetaminophen levels in prescription painkillers like Vicodin and Percocet.

Judge Stengel is presiding over pretrial proceedings in the Tylenol litigation, and it is expected that a series of early “bellwether” trials will be scheduled to help the parties gauge how juries are likely to respond to certain evidence or testimony that may be repeated throughout a large number of cases. The outcome of these proceedings may help facilitate individual settlement agreements for individuals who suffered liver failure from Tylenol. However, if a resolution is not reached following the MDL proceedings, each case may be remanded back to the U.S. District Court where it was originally filed for a separate trial date.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic and Rybelsus Side Effects Led to Ileus, Nausea and Vomiting, Lawsuit Alleges
Ozempic and Rybelsus Side Effects Led to Ileus, Nausea and Vomiting, Lawsuit Alleges (Posted today)

A Kentucky man's lawsuit claims Ozempic and Rybelsus side effects led to multiple trips to the emergency room due to nausea, vomiting and other reactions to his intestinal muscles being unable to push food through his digestive tract.

Multi-Day Suboxone Lawsuit Status Conference Being Held To Review Census Protocol and Procedures
Multi-Day Suboxone Lawsuit Status Conference Being Held To Review Census Protocol and Procedures (Posted today)

Lawyers will be meeting with the MDL judge presiding over all Suboxone tooth decay lawsuits on October 4 and 5, 2024, to finalize information needed to select a group of representative cases for bellwether discovery and trial.

Bard Settlement Reached To Resolve Hernia Mesh Lawsuits, With “Multi-Year” Payout Structure
Bard Settlement Reached To Resolve Hernia Mesh Lawsuits, With “Multi-Year” Payout Structure (Posted yesterday)

Lawyers have reached a confidential settlement agreement to resolve tens of thousands of Bard hernia mesh lawsuits after six years of litigation, but individuals must still agree to participate and settle their claims.